| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MITF |
| Uniprot No | O75030 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-520aa |
| 氨基酸序列 | MLEMLEYNHYQVQTHLENPTKYHIQQAQRQQVKQYLSTTLANKHANQVLSLPCPNQPGDH VMPPVPGSSAPNSPMAMLTLNSNCEKEGFYKFEEQNRAESECPGMNTHSRASCMQMDDVI DDIISLESSYNEEILGLMDPALQMANTLPVSGNLIDLYGNQGLPPPGLTISNSCPANLPN IKRELTESEARALAKERQKKDNHNLIERRRRFNINDRIKELGTLIPKSNDPDMRWNKGTI LKASVDYIRKLQREQQRAKELENRQKKLEHANRHLLLRIQELEMQARAHGLSLIPSTGLC SPDLVNRIIKQEPVLENCSQDLLQHHADLTCTTTLDLTDGTITFNNNLGTGTEANQAYSV PTKMGSKLEDILMDDTLSPVGVTDPLLSSVSPGASKTSSRRSSMSMEETEHTC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MITF重组蛋白的3篇示例参考文献(注：文献信息为模拟示例，仅供参考)：
---
1. **文献名称**: "Recombinant MITF Protein Purification and DNA-Binding Activity Analysis"
**作者**: Chen L, et al.
**摘要**: 本研究报道了人源MITF重组蛋白在大肠杆菌中的高效表达与纯化，通过凝胶迁移实验(EMSA)证实其特异性结合下游基因启动子区的E-box元件，为体外研究MITF的转录调控机制提供工具。
2. **文献名称**: "Structural Insights into MITF Regulation by Post-Translational Modifications"
**作者**: Roberts KG, et al.
**摘要**: 利用重组MITF蛋白进行磷酸化位点突变实验，结合晶体结构分析，揭示了磷酸化修饰如何调控MITF的蛋白稳定性及其与协同转录因子(如TFEB)的相互作用。
3. **文献名称**: "MITF-Driven Melanoma Cell Invasion Requires Recombinant MITF Dimerization"
**作者**: Gupta S, et al.
**摘要**: 通过体外重构MITF重组蛋白，证明其二聚化结构域对激活黑色素瘤细胞侵袭相关基因(如TYRP1)不可或缺，并筛选出小分子抑制剂阻断其功能。
---
如需真实文献，建议通过PubMed或Web of Science检索关键词“MITF recombinant protein”获取最新研究。
**Background of MITF Recombinant Protein**
The Microphthalmia-associated transcription factor (MITF) is a critical regulator belonging to the basic helix-loop-helix leucine zipper (bHLH-Zip) family of transcription factors. Initially identified for its role in melanocyte development and pigmentation, MITF governs the expression of genes involved in melanin synthesis (e.g., tyrosinase, TYR) and cell survival. Beyond melanocytes, MITF is essential in other cell types, including osteoclasts (bone resorption), mast cells (immune response), and retinal pigment epithelial cells, highlighting its pleiotropic functions. Dysregulation of MITF is linked to pathologies such as melanoma, Waardenburg syndrome (pigmentation disorders), and osteoporosis.
Recombinant MITF protein is engineered using DNA cloning techniques, often expressed in *E. coli* or mammalian systems to ensure proper post-translational modifications. This purified protein retains functional domains, including the DNA-binding basic domain, HLH-Zip motif for dimerization, and transactivation domains, enabling studies on its molecular interactions. Researchers utilize recombinant MITF to dissect mechanisms of gene regulation, cellular differentiation, and disease pathways. For instance, in melanoma, MITF’s dual role as an oncogene or tumor suppressor depends on its expression levels and context, making it a therapeutic target.
Additionally, recombinant MITF aids in drug discovery, screening for inhibitors that modulate its activity in cancers or pigmentary disorders. Its role in osteoclastogenesis also offers insights into bone diseases. By providing a controlled, scalable source of functional MITF, recombinant technology accelerates both basic research and translational applications, bridging molecular insights to clinical solutions.
×
